Eli Lilly (LLY) is reportedly expanding its pharmaceutical pipeline through a new agreement involving Clazakizumab, as reported by Reuters.

The initial excitement surrounding GLP-1 weight loss drugs provides insights into current market dynamics, with connections drawn to jet fuel and software sell-offs.

CSL has entered into a licensing agreement with Eli Lilly for clazakizumab, a treatment for kidney disease.